Latest News
M&As this week: Epiva Biosciences, Nichi-iko Pharma, Cell Medica
Immunobiotic therapeutics developer Epiva Biosciences has merged with immune-microbiome company Evelo Biosciences to develop new therapeutics for cancer, autoimmune and inflammatory...
M&As this week: Accuron Technologies, Nantong Jinghua Pharma
Accuron Technologies plans to further develop its suite of medical devices outsourcing services through its recent acquisition of a majority stake in Aurum Healthcare, a provider of...
Deals this week: Takeda Pharma, Pfizer, Huons Global
Takeda Pharma and Altos Therapeutics have entered a definitive agreement to jointly develop a treatment for gastroparesis...
Report: GSK’s MenABCWY Vaccine to propel Meningococcal disease prevention market to reach $1.8bn
The meningococcal disease prevention market is set to grow to $1.8bn driven by the introduction of GlaxoSmithKline’s (GSK) MenABCWY vaccine, according to a report by GlobalData....
Report: Diabetes complications space set to improve with many innovative first-in-class products in pipeline
A GBI Research report reveals that the market for diabetes complication will undergo improvements and changes brought about by greater awareness and...
M&As this week: Shilpa Medicare, Charles River Labs, Mercal Capital
Active pharmaceutical ingredient manufacturer Shilpa Medicare plans to merge with Navya Biologicals Private Limited, a company engaged in biologics and biosimilars...
Deals this week: IBM Research-Australia, Cure Forward, Agilis Biotherapeutics
IBM Research-Australia and Melanoma Institute Australia have entered a research agreement to further pursue research on the identification of early stages of melanoma using cognitive...
Deals this week: Kite Pharma, Waters Corporation, Retrophin Inc.
Kite Pharma and Experimental Transplantation and Immunology Branch (ETIB) of National Cancer Institute (NCI) have entered a co-operative research and development (R&D) agreement (CRADA) to...
Report: Pharmaceutical companies to focus on first-in-class treatments to earn higher revenues and maximise growth options
First-in-class treatments will dominate the pharmaceutical industry with more companies shifting focus towards developing novel products, says a report by GBI Research....
M&As this week: QLT, Carbylan Therapeutics
Biotechnology company QLT has announced to acquire Aegerion Pharmaceuticals through its wholly-owned, indirect subsidiary Isotope Acquisition Corp (MergerCo.) to diversify its portfolio...
Report: Targeting the vector instead of virus can combat mosquito-borne diseases in the long-run
Pharmaceutical and biotechnology companies must focus on developing a long-term solution to mosquito-borne diseases rather than just targeting a single virus such as the Zica, according to a...
Deals this week: EnBiotix, Oncolys BioPharma, ImmunoGen
EnBiotix and Mayo Clinic have entered a partnership to advance the development of EPP-001, a drug candidate for the treatment of prosthetic joint...
Senhwa enrolls patient in Phase I/II CX-5461 trial in triple-negative breast cancer patients
Senhwa Biosciences has enrolled its first patient in a multicentre phase I/II clinical trial to study its investigational product CX-5461 in triple-negative breast cancer (TNBC) patients...
M&As this week: Jaguar Holding Company, Searchlight Pharma
Jaguar Holding Company, a holding company of Pharmaceutical Product Development (PPD), has acquired Synexus Clinical Research from LDC (Managers) for a sale consideration of...
Report: Meningococcal vaccines market to be propelled by inclusive vaccination schedules
The market for meningococcal vaccines is projected to expand at a compound annual growth rate of 5.4% to reach $1.8bn in value by 2025, according to a recent report by...
Deals this week: Bristol-Myers Squibb, Seres Therapeutics, Flexion Therapeutics
Bristol-Myers Squibb has entered a clinical research agreement with University of Texas MD Anderson Cancer Centre to further investigate new strategies for treating lung cancer, using...
Report: Opdivo set to have biggest share in renal cell carcinoma market by 2023
Opdivo is projected to lead the growth in renal cell carcinoma (RCC) market and be a market leader by 2023, according to a report by...
M&As this week: Augment Investments, Recordati
Augment Investments has announced its acquirement of an additional 10.032% stake in Pharmstandard OJSC, from Bristley Enterprises, to become a 79.8% stake holder in the company, upon the...
Deals this week: BioRap Technologies, Saniona AB, Mylan N.V
BioRap Technologies and Pfizer have entered a co-development agreement to improve the research and development of novel immunomodulators, which will help in introducing new treatment options...
M&As this week: Biodel, Luraq Investments and Chengdu Huasun
Biodel and Albireo have entered a definitive share exchange agreement for a merger aimed at developing novel bile acid modulators to liver and gastrointestinal diseases and...
Deals this week: TriNetX, Astellas Pharma and Noden Pharma
TriNetX and Celgene have entered a partnership to further develop clinical trial design and research for next-generation...
